KalVista Pharmaceuticals, Inc. 8-K

What Happened
KalVista Pharmaceuticals announced on January 8, 2026 that preliminary global net revenue was approximately $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. The company issued a press release and an updated corporate presentation to disclose these figures.

Key Details

• Preliminary global net revenue: ~ $35 million for the quarter ended Dec 31, 2025.
• Preliminary global net revenue: ~ $49 million for the eight‑month transition period ended Dec 31, 2025.
• Audited financial statements for the eight‑month transition period are not yet available; the figures are estimates subject to financial close and audit adjustments and may differ materially.
• The company furnished a press release and updated corporate presentation (Exhibits 99.1 and 99.2) on Jan 8, 2026.

Why It Matters
These preliminary revenue figures give investors an early view of KalVista’s recent sales performance, but they are unaudited and conditional on the completion of closing procedures and the audit. Investors should treat the numbers as estimates until the company files audited financial statements and full quarterly/period results, as the final amounts could change materially.